1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Drug Pricing

Procurement Must Look Beyond Price To Ensure Supply Chain Security

Criteria Must Reward Non-Price Aspects In Wake Of COVID-19

 
• By Dave Wallace

A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.

Drugs
Medicines procurement criteria must go beyond price • Source: Shutterstock

In the first part of our interview with James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – he laid out the key actions taken by the European generics industry to mitigate the coronavirus pandemic over the past weeks and months. (Also see "European Industry Played Key Role In Mitigating COVID-19" - Generics Bulletin, 30 July, 2020.)

Now, in the second part of our exclusive interview, Burt tells Generics Bulletin what the off-patent industry can expect in terms of the future fallout from COVID-19, as well as what changes need to be made to ensure a more sustainable environment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Governor Newsom Expands Discounted Naloxone Availability To All Californians

 
• By Adam Zamecnik

After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By Dave Wallace

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

 
• By Dave Wallace

In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.

More from Policy & Regulation

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

French Body Welcomes Call For Greater Uptake

 
• By Dave Wallace

French generics and biosimilar body Gemme has welcomed a call from the country’s audit court to improve uptake for off-patent medicines.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.